Efficacy News and Research

RSS
Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Exelixis and NCI's CTEP enter CRADA to further evaluate cabozantinib

Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine

Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine

HGNS increases airflow during sleep in patients with OSA

HGNS increases airflow during sleep in patients with OSA

AMP opposes NIH proposal to license cancer-related proteonomics patent

AMP opposes NIH proposal to license cancer-related proteonomics patent

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Celgene to discontinue docetaxel and prednisone plus lenalidomide Phase III trial on CRPC

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

Treatment of Type 1 diabetes patients with DiaPep277- may have several medical benefits

Arginine may reactivate T-cells in patients with glioblastoma

Arginine may reactivate T-cells in patients with glioblastoma

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

FDA accepts Regeneron's ARCALYST sBLA for review

FDA accepts Regeneron's ARCALYST sBLA for review

Naltrexone for problem gamblers

Naltrexone for problem gamblers

Merck agrees to pay $950 million in Vioxx safety probe

Merck agrees to pay $950 million in Vioxx safety probe

New way to exploit expression of BRAF by papillary carcinomas for therapeutic purposes

New way to exploit expression of BRAF by papillary carcinomas for therapeutic purposes

Scientists identify new immune system defect in aged mice

Scientists identify new immune system defect in aged mice

FDA accepts Otsuka's aripiprazole depot formulation NDA for review

FDA accepts Otsuka's aripiprazole depot formulation NDA for review

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

ADA Seal of Acceptance helps consumers make informed decisions about dental products

ADA Seal of Acceptance helps consumers make informed decisions about dental products

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Gilead enters agreement for Pharmasset acquisition

Gilead enters agreement for Pharmasset acquisition

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.